多发性骨髓瘤(MM)是一种不可治愈的恶性单克隆浆细胞病,目前的治疗包括MP方案或联合其他化疗药物如长春新碱、阿霉素。尽管大剂量化疗和骨髓移植使骨髓瘤患者的缓解期得到一定的改善,然而MM最终将进展到耐药或难治的状态,中位生存期在3年左右[1],5年生存率不到25%[2],因此一些 Multiple myeloma (MM) is an incurable malignant monoclonal plasma cell disease and current treatments include the MP regimen or in combination with other chemotherapy drugs such as vincristine and doxorubicin. Although high-dose chemotherapy and bone marrow transplantation in patients with myeloma remission to some improvement, however, MM will eventually progress to drug-resistant or refractory state, the median survival of about 3 years [1], 5-year survival rate is not To 25% [2], so some